Medical Litigation News and Research

RSS

Appeals court affirms that J&J stents infringe Boston Scientific patent

Boston Scientific Corporation has announced that the Court of Appeals for the Federal Circuit issued a decision in the Company's stent litigation with Johnson and Johnson (J&J).

1 Apr 2009

New tool in the radiography approach will assist in earlier detection of asbestos-related diseases

Michael Harbut, M.D., MPH, co-director of the National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) at the Barbara Ann Karmanos Cancer Institute in Detroit, MI, and chief of the Center for Occupational and Environmental Medicine Wayne State University, announced the use of a new technology to aid in the diagnosis of asbestos-related lung disease.

30 Mar 2009

German Federal Patent Court invalidates Wake Forest NPWT patents licensed to KCI

Smith & Nephew Inc.'s Advanced Wound Management division announced that the German Federal Patent Court in Munich has held the Wake Forest patent for negative pressure (NPWT) licensed to Kinetic Concepts, Inc. invalid in Germany.

17 Mar 2009

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Eli Lilly and Company has issued the following statement after being granted a temporary restraining order to halt the launch of a generic version of Evista (raloxifene HCl tablets) by Teva Pharmaceuticals.

11 Mar 2009

Supreme Court rules against Wyeth in pre-emption case

The U.S. Supreme Court on Wednesday ruled 6-3 that consumers harmed by an FDA-approved pharmaceutical product can sue the drugmaker for liability in state courts, the San Francisco Chronicle reports (Egelko, San Francisco Chronicle, 3/5).

5 Mar 2009

Endo and Penwest announce settlement of Opana ER litigation

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Actavis South Atlantic LLC regarding the production and sale of generic formulations of Opana(R) ER (oxymorphone hydrochloride) Extended Release Tablets CII.

22 Feb 2009

U.S. Court of Federal Claims declares vaccines do not cause autism

The three judges ruled that the measles-mumps-rubella vaccine (MMR), given in combination with thimerosal-containing vaccines, does not cause autism.

17 Feb 2009

Risk of malpractice lawsuits in breast imaging overestimate by radiologists

Radiologists who work in breast imaging tend to overestimate their actual risk of medical malpractice lawsuits, according to a study performed at the University of Washington School of Public Health and Community Medicine in Seattle, WA.

2 Feb 2009

Recent reports regarding mercury and high fructose

ChemRisk, a leading scientific consulting firm, was asked by the Corn Refiners Association (CRA) to examine the recent publication by Institute for Agriculture and Trade Policy (IATP), "Not So Sweet: Missing Mercury and High Fructose Corn Syrup," and the Environmental Health journal publication "Mercury from chlor-alkali plants: measured concentrations in food product sugar," by Dufault et al, 2009, and to offer our comments and analysis.

2 Feb 2009

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today.

19 Jan 2009

Sun Pharmaceutical extends tender offer for Taro

Sun Pharmaceutical Industries Ltd. today announced its subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), has extended the Expiration Date of the Tender Offer for the purchase of all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro).

7 Jan 2009

Endo Pharmaceuticals to acquire Indevus Pharmaceuticals

Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.

5 Jan 2009

Informed consent process has lost its educational value

It's time patient consent forms came back full circle to a tool for patient education, rather than the waiver of liability they have become.

17 Dec 2008

ZOLL Medical cleared to market defibrillator with WiFi option

ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the ZOLL R Series Code-Ready clinical defibrillator with a WiFi option that allows wireless communication between the defibrillator and standard hospital networks to help ensure code-readiness and download patient data.

16 Dec 2008

Prescription for improvements in patient safety

A major reform of the way that NHS hospitals pay for legal liability insurance has led to improvements in patient safety, according to research funded by the Economic and Social Research Council.

30 Nov 2008

Deregistered cancer doctor in denial about risking 6,770 lives

A former Sydney skin cancer doctor who may have jeopardised the health of thousands of his former patients is apparently planning to appeal against his deregistration.

26 Nov 2008

Teva announces agreement on generic Pulmicort Respules patent challenge

Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva's U.S. generic version of AstraZeneca's Pulmicort (Budesonide) Respules including all claims for patent infringement and damages.

25 Nov 2008

AstraZeneca settles U.S. Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals

AstraZeneca has announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA.

25 Nov 2008

Launch of new safety hypodermic needle

Covidien has announced that it is launching a new and improved Magellan Safety Hypodermic Needle.

19 Nov 2008

Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges

Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets.

19 Nov 2008